The Immune Microenvironment in Basal Cell Carcinoma

키워드

참고문헌 (149)

1. Asgari MM, "Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998-2012", JAMA Dermatol, 151, pp.976~981 (2015)
2. Verkouteren JAC, "Epidemiology of basal cell carcinoma : scholarly review", Br J Dermatol, 177, pp.359~372 (2017)
3. Kantor J, "The epidemiology of skin cancer in Asia : September 2021", J Am Acad Dermatol, 85, pp.569~ (2021)
4. Ichihashi M, "Trends in nonmelanoma skin cancer in Japan", Recent Results Cancer Res, 139, pp.263~273 (1995)
5. Wu S, "Basal-cell carcinoma incidence and associated risk factors in U. S. women and men", Am J Epidemiol, 178, pp.890~897 (2013)
6. Cameron MC, "Basal cell carcinoma : epidemiology; pathophysiology; clinical and histological subtypes; and disease associations", J Am Acad Dermatol, 80, pp.303~317 (2019)
7. Khalesi M, "A meta-analysis of pigmentary characteristics, sun sensitivity, freckling and melanocytic nevi and risk of basal cell carcinoma of the skin", Cancer Epidemiol, 37, pp.534~543 (2013)
8. Chinem VP, "Prevalence of actinic skin lesions in patients with basal cell carcinoma of the head: a case-control study", Rev Assoc Med Bras(1992), 58, pp.188~196 (2012)
9. Oh CC, "Trends of cutaneous basal cell carcinoma, squamous cell carcinoma, and melanoma among the Chinese, Malays, and Indians in Singapore from 1968-2016", JAAD Int, 4, pp.39~45 (2021)
10. Kikuchi A, "Clinical histopathological characteristics of basal cell carcinoma in Japanese patients", Arch Dermatol, 132, pp.320~324 (1996)
11. Moore MG, "Basal cell carcinoma in asians : a retrospective analysis of ten patients", J Skin Cancer, 2012, pp.741397~ (2012)
12. Scrivener Y, "Variations of basal cell carcinomas according to gender, age, location and histopathological subtype", Br J Dermatol, 147, pp.41~47 (2002)
13. Gupta R, "Clinical characteristics of basal cell carcinoma in African Americans : a 10-year retrospective review at a single academic institution", Dermatol Surg, 45, pp.660~665 (2019)
14. Cho S, "Clinical and histopathological characteristics of basal cell carcinoma in Korean patients", J Dermatol, 26, pp.494~501 (1999)
15. Moon HR, "Pigmentation of basal cell carcinoma is inversely associated with tumor aggressiveness in Asian patients", J Am Acad Dermatol, 80, pp.1755~1757 (2019)
16. 노기웅, "Subclinical Infiltration of Basal Cell Carcinoma in Asian Patients: Assessment after Mohs Micrographic Surgery", Annals of Dermatology, 23(3), pp.276~281 (2011), 대한피부과학회
17. Raasch BA, "Basal cell carcinoma : histological classification and body-site distribution", Br J Dermatol, 155, pp.401~407 (2006)
18. Bichakjian CK, "Basal cell skin cancer, version 1. 2016, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 14, pp.574~597 (2016)
19. Kricker A, "Sun exposure and nonmelanocytic skin cancer", Cancer Causes Control, 5, pp.367~392 (1994)
20. Bonilla X, "Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma", Nat Genet, 48, pp.398~406 (2016)
21. Jayaraman SS, "Mutational landscape of basal cell carcinomas by whole-exome sequencing", J Invest Dermatol, 134, pp.213~220 (2014)
22. Tran H, "Epidemiology and aetiology of basal cell carcinoma", Br J Dermatol, 149(Suppl 66), pp.50~52 (2003)
23. Shore RE, "Skin cancer after X-ray treatment for scalp ringworm", Radiat Res, 157, pp.410~418 (2002)
24. Yu HS, "Arsenic carcinogenesis in the skin", J Biomed Sci, 13, pp.657~666 (2006)
25. Chenevix-Trench G, "Further localization of the gene for nevoid basal cell carcinoma syndrome(NBCCS)in 15 Australasian families : linkage and loss of heterozygosity", Am J Hum Genet, 53, pp.760~767 (1993)
26. Bialer MG, "Prenatal diagnosis of Gorlin syndrome", Lancet, 344, pp.477~ (1994)
27. Pellegrini C, "Understanding the molecular genetics of basal cell carcinoma", Int J Mol Sci, 18, pp.2485~ (2017)
28. Xie J, "Activating Smoothened mutations in sporadic basal-cell carcinoma", Nature, 391, pp.90~92 (1998)
29. Dahmane N, "Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours", Nature, 389, pp.876~881 (1997)
30. Gailani MR, "The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas", Nat Genet, 14, pp.78~81 (1996)
31. Kripke ML, "Antigenicity of murine skin tumors induced by ultraviolet light", J Natl Cancer Inst, 53, pp.1333~1336 (1974)
32. Damian DL, "Topical riboflavin attenuates ultraviolet B-and ultraviolet A-induced immunosuppression in humans", Photodermatol Photoimmunol Photomed, 26, pp.66~69 (2010)
33. Matthews YJ, "A UVB wavelength dependency for local suppression of recall immunity in humans demonstrates a peak at 300 nm", J Invest Dermatol, 130, pp.1680~1684 (2010)
34. Gibbs NK, "Urocanic acid in the skin : a mixed blessing?", J Invest Dermatol, 131, pp.14~17 (2011)
35. Tabachnick J, "Urocanic acid, the major acid-soluble, ultraviolet-absorbing compound in guinea pig epidermis", Arch Biochem Biophys, 70, pp.295~298 (1957)
36. Kurogochi Y, "A note on cisurocanid acid", Jpn J Pharmacol, 6, pp.147~152 (1957)
37. Barresi C, "Increased sensitivity of histidinemic mice to UVB radiation suggests a crucial role of endogenous urocanic acid in photoprotection", J Invest Dermatol, 131, pp.188~194 (2011)
38. Kurimoto I, "cis-urocanic acid suppression of contact hypersensitivity induction is mediated via tumor necrosis factoralpha", J Immunol, 148, pp.3072~3078 (1992)
39. Pham DL, "Increased cis-to-trans urocanic acid ratio in the skin of chronic spontaneous urticaria patients", Sci Rep, 7, pp.1318~ (2017)
40. Marathe GK, "Ultraviolet B radiation generates platelet-activating factorlike phospholipids underlying cutaneous damage", J Biol Chem, 280, pp.35448~35457 (2005)
41. Pei Y, "Activation of the epidermal platelet-activating factor receptor results in cytokine and cyclooxygenase-2 biosynthesis", J Immunol, 161, pp.1954~1961 (1998)
42. Tjiu JW, "Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis", J Invest Dermatol, 126, pp.1143~1151 (2006)
43. Tjiu JW, "Tumorassociated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction", J Invest Dermatol, 129, pp.1016~1025 (2009)
44. Kripke ML, "Pyrimidine dimers in DNA initiate systemic immunosuppression in UV-irradiated mice", Proc Natl Acad Sci U S A, 89, pp.7516~7520 (1992)
45. Yarosh DB, "After sun reversal of DNA damage : enhancing skin repair", Mutat Res, 571, pp.57~64 (2005)
46. Stege H, "Enzyme plus light therapy to repair DNA damage in ultraviolet-B-irradiated human skin", Proc Natl Acad Sci U S A, 97, pp.1790~1795 (2000)
47. Yarosh D, "Localization of liposomes containing a DNA repair enzyme in murine skin", J Invest Dermatol, 103, pp.461~468 (1994)
48. Damian DL, "Topical calcitriol protects from UV-induced genetic damage but suppresses cutaneous immunity in humans", Exp Dermatol, 19, pp.e23~e30 (2010)
49. Hanneman KK, "Effect of topical vitamin D analogue on in vivo contact sensitization", Arch Dermatol, 142, pp.1332~1334 (2006)
50. Ferreira GB, "1α, 25-Dihydroxyvitamin D3 and its analogs as modulators of human dendritic cells : a comparison dose-titration study", J Steroid Biochem Mol Biol, 136, pp.160~165 (2013)
51. van der Aar AM, "Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells", J Allergy Clin Immunol, 127, pp.1532~1540 (2011)
52. Park SM, "Vitamin D intake and risk of skin cancer in US women and men", PLoS One, 11, pp.e0160308~ (2016)
53. Mahamat-Saleh Y, "25-Hydroxyvitamin D status, vitamin D intake, and skin cancer risk : a systematic review and dose-response meta-analysis of prospective studies", Sci Rep, 10, pp.13151~ (2020)
54. Mittal A, "Skin cancers in organ transplant recipients", Am J Transplant, 17, pp.2509~2530 (2017)
55. Hartevelt MM, "Incidence of skin cancer after renal transplantation in The Netherlands", Transplantation, 49, pp.506~509 (1990)
56. Fortina AB, "Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients", Arch Dermatol, 140, pp.1079~1085 (2004)
57. Glover MT, "Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients", Lancet, 349, pp.398~ (1997)
58. Krynitz B, "Risk of basal cell carcinoma in Swedish organ transplant recipients : a population-based study", Br J Dermatol, 174, pp.95~103 (2016)
59. Frezza EE, "Non-lymphoid cancer after liver transplantation", Hepatogastroenterology, 44, pp.1172~1181 (1997)
60. Perera GK, "Skin lesions in adult liver transplant recipients : a study of 100 consecutive patients", Br J Dermatol, 154, pp.868~872 (2006)
61. Funk-Debleds P, "Subsequent nonmelanoma skin cancers and impact of immunosuppression in liver transplant recipients", J Am Acad Dermatol, 79, pp.84~91 (2018)
62. Kanitakis J, "Basal cell carcinomas developing in solid organ transplant recipients : clinicopathologic study of 176 cases", Arch Dermatol, 139, pp.1133~1137 (2003)
63. Mertz KD, "Basal cell carcinoma in a series of renal transplant recipients : epidemiology and clinicopathologic features", Int J Dermatol, 49, pp.385~389 (2010)
64. Laurent C, "Several immune escape patterns in non-Hodgkin's lymphomas", Oncoimmunology, 4, pp.e1026530~ (2015)
65. Nijland M, "HLA dependent immune escape mechanisms in B-cell lymphomas : implications for immune checkpoint inhibitor therapy?", Oncoimmunology, 6, pp.e1295202~ (2017)
66. Mittal S, "Local and systemic induction of CD4+CD25+ regulatory Tcell population by non-Hodgkin lymphoma", Blood, 111, pp.5359~5370 (2008)
67. Lin Y, "Immunosuppressive CD14+HLA-DR(low)", -monocytes in Bcell non-Hodgkin lymphoma, 2011, pp.117, 872~881
68. Mellemgaard A, "Risk of kidney cancer and other second solid malignancies in patients with chronic lymphocytic leukemia", Eur J Haematol, 53, pp.218~222 (1994)
69. Brewer JD, "Lymphoma-associated skin cancer : incidence, natural history, and clinical management", Int J Dermatol, 53, pp.267~274 (2014)
70. Levi F, "Non-Hodgkin's lymphomas, chronic lymphocytic leukaemias and skin cancers", Br J Cancer, 74, pp.1847~1850 (1996)
71. Manusow D, "Subsequent neoplasia in chronic lymphocytic leukemia", JAMA, 232, pp.267~269 (1975)
72. Brewer JD, "Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma : a Rochester Epidemiology Project population-based study in Minnesota", J Am Acad Dermatol, 72, pp.302~309 (2015)
73. Agnew KL, "Cutaneous findings in chronic lymphocytic leukaemia", Br J Dermatol, 150, pp.1129~1135 (2004)
74. Hjalgrim H, "Non-melanoma skin cancer may be a marker of poor prognosis in patients with non-Hodgkin's lymphoma", Int J Cancer, 85, pp.639~642 (2000)
75. Mehrany K, "High recurrence rates of Basal cell carcinoma after mohs surgery in patients with chronic lymphocytic leukemia", Arch Dermatol, 140, pp.985~988 (2004)
76. Silverberg MJ, "HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer", J Natl Cancer Inst, 105, pp.350~360 (2013)
77. Burgi A, "Incidence and risk factors for the occurrence of non-AIDSdefining cancers among human immunodeficiency virus-infected individuals", Cancer, 104, pp.1505~1511 (2005)
78. Zhao H, "The risk of non-melanoma skin cancer in HIV-infected patients : new data and meta-analysis", Int J STD AIDS, 27, pp.568~575 (2016)
79. Crum-Cianflone N, "Cutaneous malignancies among HIV-infected persons", Arch Intern Med, 169, pp.1130~1138 (2009)
80. Asgari MM, "Association of multiple primary skin cancers with human immunodeficiency virus infection, CD4 count, and viral load", JAMA Dermatol, 153, pp.892~896 (2017)
81. Habets JM, "Characterization of the mononuclear infiltrate in basal cell carcinoma : a predominantly T cell-mediated immune response with minor participation of Leu-7+(natural killer)cells and Leu-14+(B)cells", J Invest Dermatol, 90, pp.289~292 (1988)
82. Dellon AL, "The immunobiology of skin cancer", Plast Reconstr Surg, 55, pp.341~354 (1975)
83. Viac J, "Characterization of mononuclear cells in the inflammatory infiltrates of cutaneous tumours", Br J Dermatol, 97, pp.1~10 (1977)
84. De Panfilis G, "In situ identification of mononuclear cells infiltrating cutaneous carcinoma : an immuno-histochemical study", Acta Derm Venereol, 59, pp.219~222 (1979)
85. Deng JS, "Immune-associated cells in basal cell carcinomas of skin", J Cutan Pathol, 23, pp.140~146 (1996)
86. Omland SH, "Immunosuppressive environment in basal cell carcinoma : the role of regulatory T cells", Acta Derm Venereol, 96, pp.917~921 (2016)
87. Kaporis HG, "Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment", J Invest Dermatol, 127, pp.2391~2398 (2007)
88. Hunt MJ, "Regression in basal cell carcinoma : an immunohistochemical analysis", Br J Dermatol, 130, pp.1~8 (1994)
89. Fujimura T, "Basal cell carcinoma with spontaneous regression : a case report and immunohistochemical study", Case Rep Dermatol, 4, pp.125~132 (2012)
90. Herwig-Carl MC, "Regression of periocular basal cell carcinoma : a report of four cases with clinicopathologic correlation", Ocul Oncol Pathol, 6, pp.107~114 (2020)
91. Wong DA, "Cytokine profiles in spontaneously regressing basal cell carcinomas", Br J Dermatol, 143, pp.91~98 (2000)
92. Nardinocchi L, "Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer", Eur J Immunol, 45, pp.922~931 (2015)
93. Pellegrini C, "Expression of IL-23", Th17-related cytokines in basal cell carcinoma and in the response to medical treatments, 2017, pp.12, e0183415~
94. Beksaç B, "Sparsity of dendritic cells and cytotoxic T cells in tumor microenvironment may lead to recurrence in basal cell carcinoma", Int J Dermatol, 59, pp.1258~1263 (2020)
95. Aoki M, "Mast cells in basal cell carcinoma express VEGF, IL-8 and RANTES", Int Arch Allergy Immunol, 130, pp.216~223 (2003)
96. Erkiliç S, "The significance of mast cells associated with basal cell carcinoma", J Dermatol, 28, pp.312~315 (2001)
97. Diaconu NC, "Increase in CD30 ligand", CD153 and TNF-alpha expressing mast cells in basal cell carcinoma, 2007, pp.56, 1407~1415
98. Dusingize JC, "Cigarette smoking and the risks of basal cell carcinoma and squamous cell carcinoma", J Invest Dermatol, 137, pp.1700~1708 (2017)
99. Erbagci Z, "Can smoking and", or occupational UV exposure have any role in the development of the morpheaform basal cell carcinoma? A critical role for peritumoral mast cells, 2002, pp.41, 275~278
100. Staibano S, "The prognostic significance of tumor angiogenesis in nonaggressive and aggressive basal cell carcinoma of the human skin", Hum Pathol, 27, pp.695~700 (1996)
101. Starkey JR, "Mast-cell-deficient W", Wv mice exhibit a decreased rate of tumor angiogenesis, 1988, pp.42, 48~52
102. Ch'ng S, "Mast cells and cutaneous malignancies", Mod Pathol, 19, pp.149~159 (2006)
103. Harizi H, "Cyclooxygenase-2-issued prostaglandin e(2)enhances the production of endogenous IL-10, which down-regulates dendritic cell functions", J Immunol, 168, pp.2255~2263 (2002)
104. Wille JJ, "cis-urocanic acid induces mast cell degranulation and release of preformed TNF-alpha : a possible mechanism linking UVB and cis-urocanic acid to immunosuppression of contact hypersensitivity", Skin Pharmacol Appl Skin Physiol, 12, pp.18~27 (1999)
105. Yamamoto T, "Expression of stem cell factor in basal cell carcinoma", Br J Dermatol, 137, pp.709~713 (1997)
106. Grimbaldeston MA, "Increased dermal mast cell prevalence and susceptibility to development of basal cell carcinoma in humans", Methods, 28, pp.90~96 (2002)
107. Hart PH, "Dermal mast cells determine susceptibility to ultraviolet B-induced systemic suppression of contact hypersensitivity responses in mice", J Exp Med, 187, pp.2045~2053 (1998)
108. Metz M, "Inflammatory murine skin responses to UV-B light are partially dependent on endothelin-1 and mast cells", Am J Pathol, 169, pp.815~822 (2006)
109. Smolle J, "Langerhans cell density in epithelial skin tumors correlates with epithelial differentiation but not with the peritumoral infiltrate", J Invest Dermatol, 87, pp.477~479 (1986)
110. Sica A, "Macrophage polarization in tumour progression", Semin Cancer Biol, 18, pp.349~355 (2008)
111. Ma PF, "Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice", J Hepatol, 67, pp.770~779 (2017)
112. Halliday GM, "Inflammation, gene mutation and photoimmunosuppression in response to UVR-induced oxidative damage contributes to photocarcinogenesis", Mutat Res, 571, pp.107~120 (2005)
113. Hwang I, "Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients", J Transl Med, 18, pp.443~ (2020)
114. Fan QM, "Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma", Cancer Lett, 352, pp.160~168 (2014)
115. Tu D, "M2 macrophages contribute to cell proliferation and migration of breast cancer", Cell Biol Int, 45, pp.831~838 (2021)
116. Padoveze EH, "Macrophage subtypes in recurrent nodular basal cell carcinoma after Mohs micrographic surgery", Int J Dermatol, 56, pp.1366~1372 (2017)
117. König S, "Depletion of cutaneous macrophages and dendritic cells promotes growth of basal cell carcinoma in mice", PLoS One, 9, pp.e93555~ (2014)
118. Minocha R, "A reduction in inflammatory macrophages may contribute to skin cancer chemoprevention by nicotinamide", J Invest Dermatol, 139, pp.467~469 (2019)
119. Santos I, "Quantitative study of Langerhans cells in basal cell carcinoma with higher or lower potential of local aggressiveness", An Bras Dermatol, 85, pp.165~171 (2010)
120. Banerjee DK, "Expansion of FOXP3high regulatory T cells by human dendritic cells(DCs)in vitro and after injection of cytokinematured DCs in myeloma patients", Blood, 108, pp.2655~2661 (2006)
121. Tang H, "Endothelial stroma programs hematopoietic stem cells to differentiate into regulatory dendritic cells through IL-10", Blood, 108, pp.1189~1197 (2006)
122. Walter A, "Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas", Clin Cancer Res, 16, pp.3562~3570 (2010)
123. Cornel AM, "MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer Immunotherapy", Cancers(Basel), 12, pp.1760~ (2020)
124. Cabrera T, "HLA molecules in basal cell carcinoma of the skin", Immunobiology, 185, pp.440~452 (1992)
125. Hua LA, "HLA and beta 2-microglobulin expression in basal and squamous cell carcinomas of the skin", Int J Dermatol, 24, pp.660~663 (1985)
126. Walter A, "Aldara activates TLR7-independent immune defence", Nat Commun, 4, pp.1560~ (2013)
127. Otsuka A, "Hedgehog signaling in basal cell carcinoma", J Dermatol Sci, 78, pp.95~100 (2015)
128. García-Plata D, "HLA molecule expression in cutaneous squamous cell carcinomas : an immunopathological study and clinical-immunohistopathological correlations", Histol Histopathol, 8, pp.219~226 (1993)
129. Kohchiyama A, "Expression of human lymphocyte antigen(HLA)-DR on tumor cells in basal cell carcinoma", J Am Acad Dermatol, 16, pp.833~838 (1987)
130. Carosella ED, "HLA-G molecules : from maternal-fetal tolerance to tissue acceptance", Adv Immunol, 81, pp.199~252 (2003)
131. Urosevic M, "Human leukocyte antigen-G and cancer immunoediting", Cancer Res, 68, pp.627~630 (2008)
132. Westin AT, "HLA-G, cytokines, and cytokine receptors in the non-aggressive basal cell carcinoma microenvironment", Arch Dermatol Res, 314, pp.247~256 (2022)
133. Elamin I, "Cytokine concentrations in basal cell carcinomas of different histological types and localization", Acta Dermatovenerol Alp Pannonica Adriat, 17, pp.55~59 (2008)
134. Kim J, "IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response", J Immunol, 155, pp.2240~2247 (1995)
135. Wilke CM, "Th17cells in cancer : help or hindrance?", Carcinogenesis, 32, pp.643~649 (2011)
136. Smeltz RB, "Role of IFN-gamma in Th1 differentiation : IFN-gamma regulates IL-18R alpha expression by preventing the negative effects of IL-4 and by inducing", maintaining IL-12 receptor beta 2 expression, 2002, pp.168, 6165~6172
137. Stanley MA, "Imiquimod and the imidazoquinolones : mechanism of action and therapeutic potential", Clin Exp Dermatol, 27, pp.571~577 (2002)
138. Urosevic M, "Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo", Arch Dermatol, 139, pp.1325~1332 (2003)
139. De Giorgi V, "In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma", Int J Dermatol, 48, pp.312~321 (2009)
140. Han Y, "PD-1", PD-L1 pathway : current researches in cancer, 2020, pp.10, 727~742
141. Lipson EJ, "Basal cell carcinoma : PD-L1", PD-1 checkpoint expression and tumor regression after PD-1 blockade, 2017, pp.5, 23~
142. Ikeda S, "Metastatic basal cell carcinoma with amplification of PD-L1 : exceptional response to anti-PD1 therapy", NPJ Genom Med, 1, pp.16037~ (2016)
143. Fischer S, "Anti-PD-1 therapy leads to near-complete remission in a patient with metastatic basal cell carcinoma", Oncol Res Treat, 41, pp.391~394 (2018)
144. Sabbatino F, "Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma : a case report and review of the literature", J Immunother Cancer, 6, pp.126~ (2018)
145. Falchook GS, "Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810", J Immunother Cancer, 4, pp.70~ (2016)
146. Goodman AM, "Genomic landscape of advanced basal cell carcinoma : implications for precision treatment with targeted and immune therapies", Oncoimmunology, 7, pp.e1404217~ (2017)
147. Stratigos AJ, "Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy : an open-label, multi-centre, single-arm, phase 2 trial", Lancet Oncol, 22, pp.848~857 (2021)
148. United States Food and Drug Administration, "FDA approves cemiplimab-rwlc for locally advanced and metastatic basal cell carcinoma", United States Food and Drug Administration, ~ (2021)
149. Mohan SV, "Incidental regression of an advanced basal cell carcinoma after ipilimumab exposure for metastatic melanoma", JAAD Case Rep, 2, pp.13~15 (2016)

관련 논문AI추천